Background: The aim of this study was to explore the effect of brain-derived neuro-
| METHODS

| Experimental protocol
A total of 38 (13 female, 25 male; mean age 70) dysphagic stroke patients were recruited to a randomized controlled trial within 6 weeks of their admission. 10 If patients were deemed to have dysphagia (determined by baseline instrumental assessments using either videofluroscopy or flexible endoscopic evaluation of swallowing 10 ) they proceeded to the treatment phase of the study within 24 hours.
Screened dysphagic patients were randomized to active or sham stimulation treatments (see below). As a nested optional component of this study, recruited patients were invited to provide a salivary DNA sample for BDNF genotyping to assess if BDNF genotype can influence swallowing recovery in response to PES.
Inclusion criteria included all patients with dysphagia that presented for the first time following acute anterior cerebral circulation or brainstem stroke, within 6 weeks from symptoms. There was no age limit but recruited patients had to be medically stable. Exclusion criteria included advanced dementia, other neurological conditions that may explain dysphagia, previous history of dysphagia, presence of cardiac pacemaker or implanted cardiac defibrillator, a diagnosis other than stroke was suspected (eg, brain tumor), any severe concomitant chronic medical condition that compromises cardiac or respiratory status (severe emphysema or heart failure that may render the insertion of the throat unsafe), and significant structural abnormalities of the mouth or throat. Patients requiring oxygen treatment were excluded at point of entry due to catheter factors so preventing further compromise to already impaired respiratory systems. Patients were reconsidered for recruitment if they were successfully weaned off oxygen treatment.
All patients continued to receive standard clinical care throughout the study as deemed appropriate by the clinicians responsible for the patient, independent of the research team.
| Experimental procedures
| Bedside examination
A trained, blinded speech and language therapist (SALT) performed a detailed bedside swallowing assessment. Their feeding recommendations were recorded before active and sham PES at baseline, and 2 weeks and 3 months after recruitment. The dysphagia severity rating scale (DSRS) reported and validated by Jayasekeran et al. to quantitate the degree of dietary adaption and feeding supervision required by the patients was the primary outcome measure (Table 1) .
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Finally, motor, functional and stroke severity information from the individuals' medical records were recorded, including the National Institutes of Health Stroke Scale (NIHSS), 25 the Modified Rankin Scale 26 and the Barthel Index. 27 These scores were taken prior to treatment and at follow-up time-points of 2 weeks and 3 months.
Key Points
• Pharyngeal electrical stimulation is a promising treatment for dysphagia after stroke. However, previous studies suggest that genetic variance may have a role in predicting outcomes following such interventions.
• We have shown that a common genetic variant in a protein called brain-derived neurotropic factor, may influence swallowing recovery after stroke in patients treated with pharyngeal electrical stimulation
• The implications of our findings are that some individuals'
with certain genes may benefit from targeted treatment after stroke and swallowing difficulty
| Pharyngeal electrical stimulation (PES)
Subjects swallowed a 3.2-mm-diameter intraluminal catheter (Gaeltec, Ltd, Dunvegan, Isle of Skye, UK), either transnasally or transorally, depending on their preference. The bipolar ring electrodes of the pharyngeal catheter were positioned intraluminally in the pharyngeal cavity, ~14 cm from the incisors or ~15 cm from the nasal flare, depending on subject preference. The maximum tolerated PES intensity was predetermined from each participant's first perceived sensation and pain threshold (the point when the pharyngeal sensation became uncomfortable), which were calculated from an average of three trials. These data were recorded.
Electrical stimulation of the pharynx was carried out using this catheter, which was connected to an electrical stimulator (Model DS7; Digitimer, Welwyn-Garden City, Herts, UK) via a trigger generator (Digitimer model DL2). Pharyngeal electrical stimuli (0.2-ms pulses, 280 V) was delivered at a set frequency (5 Hz), intensity (75% of maximal tolerated), and duration (10 minutes) as reported by Fraser.
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PES was given once a day for three consecutive days to those in the active group. In sham PES, the same method was used, including the titration steps for determining the pharyngeal stimulation intensity. However, on commencement of stimulation, the constant current generator was switched off and the intraluminal pharyngeal catheter was left in situ in the subject for the duration of intervention. The titration steps were performed by the main investigator while delivery of the actual stimulation was delivered by an assistant. Thereby, the main investigator was kept blinded to the treatment given to the patient. All patients were unaware of the treatment allocation.
| Randomization
Following consent and baseline assessment, patients were randomized through a concealed programme (Minim programme, Department of Bioengineering, Salford Royal Hospital NHS Trust, Salford, UK) provided by the trial statistician. Allocation was blocked in randomly permuted sizes and stratified by center and feeding status (presence/ absence of artificial feeding) to enhance balance. 10 The code was generated using StatsDirect software by the trial statistician and passed in confidence to the database programmer.
| Genotyping
Patients were invited as an additional component of the randomized control trial to provide a saliva sample for the acquisition of genetic 
| Protocol
PES was delivered daily to all patients for 3 days as per randomization. The dysphagia severity rating scale (DSRS- Table 1 ) was recorded independently as a summative score derived from the best score for eating, drinking, and supervision at meal times (see procedures above).
Patient measurements were taken at baseline, 2 weeks post and 3 month utilizing the same method.
| Data analysis
Statistical analyses were performed on normalized data using SPSS 15.0 (SPSS Inc, Chicago, IL, USA). We analyzed the improvement in DSRS score at 2 week and 3 month by subtracting the 2 week and 3 month scores from baseline. We then performed a linear regression analysis and compared outcomes between patients that were Val homozygous and those who were Met carriers after adjusting for patient The DSRS assigns a score to the feeding status achieved by the dysphagic patient depending on the categories of feeding stage for fluid and dietary consumption in addition to the level of dependency required for feeding. The score for each category can vary between 0 and 4 points, and is added to give a composite score. These scores were calculated by a speech and language therapist with special interest in neurogenic dysphagia.
age and stroke severity based on the NIHSS score. A similar approach was taken with the functional scores of NIHSS, Barthel, and mRS, adjusted for patient age. P≤.05 were taken as a measure of statistical significance and data are expressed as mean unless stated otherwise.
| RESULTS
While 38 dysphagic stroke patients were recruited into the clinical trial, 10 only 36 patients were randomized to either active or sham treatment. Thirty-three of the 36 patients completed the study to 3 months. A total of 20 saliva samples were acquired from the recruited patients who completed the study, and of these, 16 were of sufficient quality to be genotyped and analyzed. As reported in the clinical trial, PES was tolerated well patients by all patients and was not curtailed due to adverse effects in any patient. 10 The ages, sex distribution, and other baseline parameters for the genotyped subjects are shown in Table 2 . There were eight patients in the active group and eight in the sham group, with a distribution of 10 males and six females. The mean age (±standard deviation) of the studied group was 58.6 (±13.42) and 70.5 (±11.8) for the active and sham group, respectively. Overall mean stroke severity (±standard deviation) was 9.9 (±7.5) and 12 (±6.9) for the active and sham group, respectively, as measured by the NIHSS score. Dysphagia severity was measured by improvements in the DSRS and correlated with genotype (Table 3 ). All patients had complete DSRS data except for one patient (case 4) in the active group that had died by the 3 months period (Table 3) .
| Changes in dysphagia severity in the active and sham patient groups
The mean DSRS (±standard deviation) in the active group was 9.6 (±3.5), at the baseline and 4.1 (±4) and 1 (±1.3) at the 2 week and 3 month post intervention states, respectively. By comparison, in the sham group the mean DSRS (±standard deviation) was 6.5 (±2.7) at baseline, and 3.3 (±3.3) and 1.6 (±2.4) at the 2 week and 3 month time points, respectively.
| Association between baseline pharyngeal sensitivity and BDNF polymorphism
The average baseline pharyngeal sensitivity (±standard deviation) to stimulation in all participants was 12.9 (±5.2); while the average maximal tolerated stimulation was 21.56 (± 7.3). Logistic regression analysis revealed no statistically significant differences between genotype and baseline sensitivity (P=.72) or maximal tolerated stimulation (P=.47).
| Association between changes in dysphagia severity and BDNF polymorphism
In the actively treated group, Met carriers of the BDNF gene had sig- The Oxford Stroke Scale was used to classify stroke. LACS, lacunar stroke; PACS, partial anterior circulation stroke; POCS, posterior circulation stroke; TACI, total anterior circulation infarct; PICH, primary intracerebral hemorrhage; MCA, middle cerebral artery stroke; N/A, unknown location of stroke.
| Association between (motor) functional recovery and BDNF polymorphism
Functional recovery data as measured by the NIHSS/Barthel Index/ 
| DISCUSSION
This study aimed to test the possible influence of a single, but common BDNF polymorphism on functional recovery in a dysphagic stroke population. Specifically our hypothesis was that the BDNF polymorphism would impact on recovery after dysphagic stroke in patients treated with PES compared to sham patients. In the active group, we found that recovery can be influenced at the 3 month stage by the BDNF polymorphism.
This suggests that recovery after dysphagic stroke may be dependent on different plasticity inducing protocols associated with polymorphisms such as the BDNF Val66Met allele. Moreover, BDNF showed no correlation in the sham group suggesting that such genetic polymorphisms may be less relevant in natural recovery as compared to treatment induced recovery. Finally, we found that both pharyngeal sensitivity and functional recovery in stroke was not affected by BDNF genotype, indicating a possible behavioral specificity in the mechanism by which BDNF might act.
We observed that Met carriers demonstrated significantly greater Another further explanation is that polymorphisms in BDNF function may express differentially in disease and in health; while the Met allele may be predictive of a poor response in health, it could also paradoxically predict good recovery in the diseased state. Hypothetically, stroke may function as a trigger switching the Met allele to a protective state;
indeed, it has been observed in systemic lupus erythematosus and multiple sclerosis that the Met allele appears to be protective. 28, 29 Functionally, the Met allele in thought to result in alterations in the way the BDNF protein is trafficked intracellularly, reducing its overall secretion. However, the protein remains structurally identical. 30 It is plausible that this reduction in BDNF secretion is responsible for T A B L E 3 DSRS and genotypic data of (A) active patients and (B) sham patients improved recovery in dysphagic stroke Met carrier patients. The BDNF molecule could act as an inhibitor of motor plasticity in stroke. Indeed, it has been demonstrated in animal models that injections of BDNF into the nucleus tractus solitarii result in a rapid dose-dependent inhibition of rhythmic swallowing. 31 Furthermore, it was demonstrated that electrical stimulation of the superior laryngeal nerve reduced BDNF secretion within the dorsal vagal complex. Overall, it is clear that BDNF plays an important role in synaptic plasticity of lower level swallowing motor circuitry, and may potentially play an inhibitory role on brainstem swallowing pathways. These observations suggest that increasing levels of BDNF correlate with inhibition of swallowing. This could potentially explain why the Met allele, which results in reduced levels of BDNF, results in better swallowing outcomes after dysphagic stroke. However, this theory would not explain why in the control/sham group the Met allele did not confer the same benefit, nor would it explain why the benefits were not seen at the baseline or 2 week stage. Finally, while it is believed that the Met polymorphism results in quantitative differences rather than qualitative ones, the polymorphism could result in a subtly abnormal protein with altered functionality, which in turn may have an effect on synaptic plasticity in the pharyngeal motor cortex.
During this trial, the only parameters of PES (stimulation frequency, intensity, and dosage) utilized were the evidence-based optimized parameters based on previous studies. 8, 18 It would however be interesting in future studies to determine if the optimal parameters of PES vary between BDNF Val homozygotes and Met carriers. This hypothesis could be tested by comparing pharyngeal motor evoked potential responses as a measure of cortical excitability and swallowing reaction times 8, 32, 33 between BDNF genotype groups in healthy subjects following a 'virtual-lesion' and randomization to different parameters of PES.
In terms of limitations to our study, we recognize that the small sample size is the major limitation. In total, swallowing outcomes from 16 patients were compared, with an even split between the two treatment groups (eight active and eight sham). Within the actively treated group, there was also an even distribution between Val homozygotes and Met carriers (four in each group). While we demonstrated a significant treatment effect in
Met carriers compared to Val homozygotes, given the small sample size, one cannot exclude with certainty that these effects simply occurred by chance, and that the study was underpowered. This therefore limits our ability to make any firm conclusions. However, this is a proof-of-concept study which has achieved its objective in generating further hypotheses, and our findings will require further validation in a larger cohort.
Another limitation is that the randomization system for this trial which was designed to optimize balance between the two allocated arms, was based upon the 36 patients that were recruited into the overall study. Therefore, we cannot exclude with certainty that any observed effects of treatment induced swallowing recovery were influenced by baseline imbalances in dysphagia and stroke severity scores between the groups. However, the strength of our analyses is that the logistic regression model applied adjusted for variance in age and stroke severity between the comparative groups, which likely compensated for any such imbalances.
Other potential limitations of the study design include the recruitment window of 6 weeks following dysphagic stroke and the method to assess swallowing impairment. It is recognized that in many stroke patients, clinically relevant swallowing impairment reduces substantially 2-3 weeks after stroke onset. This may mean that our studied cohort is not representative of the average acute dysphagic stroke patient population. It may mean that our studied cohort is more likely to be patients who are more severely dysphagic or those who are recovering more slowly. Notwithstanding, it is unclear if this would have an effect on the correlation between genes and recovery after dysphagic stroke. Moreover, it has been shown in the literature that temporal improvements in swallowing function can take up to 6 months after stroke. 32 In addition, it has been shown that some patients who show a safe swallow on VFS can on a later date demonstrate impaired swallowing function on VFS. 33 Our study utilized DSRS data for improvement as compared to VFS data. The DSRS is a pragmatic scoring system based largely from observations from bedside clinical assessments of swallowing as compared to more objective measures of swallowing such as VFS. It is recognized that bedside testing would not detect silent aspiration and subtle abnormalities in the swallowing mechanism. Unfortunately, VFS data were not available in all patients in this study and therefore, we had to rely on DSRS data, which while not instrumental, has been validated in previous studies. 8, 10, 11 In conclusion, this proof of concept study suggests a novel associ- 
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